Nexira has launched its GLP-1 Collection, which contains new ingredients Carolean (carob and cactus extracts) and VinOgrape (grape extract).
The premium botanical range has been designed to promote GLP-1 secretion, support appetite control in users and manage the side effects assocaited with GLP-1 medications such as Ozempic and Wegovy.
The collection offers consumers who cannot access prescription medications the option to manage their weight naturally — though it has also been designed as a tool to assist GLP-1 medication users during and after their treatment plan.
Considering diet for weight management
As the obesity crisis continues to challenge the public and healthcare services alike, prescriptions for GLP-1 medications have surged due to their weight management potential.
Although these drugs are an option for some, not everybody is eligible for a prescription; there are also negative side effects associated with their administration, such as nausea, diarrhoea and gastrointestinal discomfort.
Therefore, many consumers are turning to natural dietary solutions that could support their weight loss journey.
Carolean, Nexira's new ingredient, encourages satiety through its rapid achievement of peak viscosity, which can help a user to feel fuller for longer.
The nutraceutical also has sustained release properties, as researche has found that Carolean can still optimise digestion with no discomfort after 80 minutes.
Comprehensive GLP-1 support
Through the GLP-1 range, Nexira has addressed a range of pain points associated with weight management, including:
- Appetite control (Carolean)
- Gut microbiome modulation (VinOgrape)
- Gastrointestinal discomfort (Inavea acacia)
- Muscle loss (Prothy carob protein, Immunell)
- Lack of energy (Ginseng, guarana, acerola)
- Gaps in nutrition (Cognivia, MCT and Simag)
This means that the company can cater to all areas of weight management — whether that be for people on GLP-1 medications or those looking to achieve results through natural dietary interventions.
In vivo study confirms Carolean's efficacy
In 2024, Nexira conducted an in vivo study, which confirmed Carolean's effectiveness as a appetite regulator.
During the three week study period, animal models experienced a significant reduction in food intake, consuming up to 47% less food than baseline.
The ingredient also significantly slowed acute and chronic gastric emptying, while promoting a two-fold increase in GLP-1 secretion.
The serum prevalence of the hunger hormone ghrelin was also reduced by 67%, suggesting that Carolean acts through multiple mechanisms to support weight loss.